Benign essential blepharospasm
Conditions
Interventions
PT Group:The PT technique used 5-site injections (4 U/s), 2 injections each in the inner and outer 1/3 of the upper eyelid (1-3 mm from the lid margin), 2 injections each in the inner and outer 1/3 of
PT-PS Joint Group:The PT-PS technique was administered at a 7-point site. Patients received additional two injections in the preseptal portion (3-5 mm from the eyelid margin), medial and lateral parts
Sponsors
Xijing Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Aged over 18 years, either male or female; (2) Have a clinical diagnosis of primary blepharospasm and have never undergone botulinum toxin injections, or have had an interval of greater than four months since their last botulinum toxin injection; (3) Have provided informed consent to participate in the trial.
Exclusion criteria
Exclusion criteria: (1) Hypersensitivity to botulinum toxin components (including botulinum toxin type A, human albumin, lactose or sodium succinate); (2) Pregnant and breastfeeding women; (3) Patients with injection site infection. (4) Patients with coagulopathies or on anticoagulant therapy; (5) Patients who have undergone periocular or eye surgery within six months; (6) Patients with skin atrophy; (7) Subjects who, in the opinion of the investigator, are not suitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| latency to therapeutic response;latency to peak response;duration of reaction;Overall efficiency; | — |
Secondary
| Measure | Time frame |
|---|---|
| satisfaction; | — |
Countries
China
Contacts
Public ContactMing Shi
Xijing Hospital, Air Force Medical University
Outcome results
None listed